No title
Background Treatment of severe hemophilia A (SHA) with FVIII concentrates is complicated by the development of neutralizing inhibitors in about 30% during the first 50 exposure days (EDs). Despite extensive research, inhibitor risk of different FVIII concentrates remains to be elucidated. Objectives This study aimed to analyze inhibitor development according to (classes of) individual FVIII concen
